Screening and Treatment Recommendations for Persons Exposed to MDR TB

Size: px
Start display at page:

Download "Screening and Treatment Recommendations for Persons Exposed to MDR TB"

Transcription

1 Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines [1, 2], this document provides specific guidance for all persons who have been identified through public health investigations as having been exposed to multidrug-resistant (MDR) TB. The initial screening should occur as soon as possible following exposure to a person with infectious TB disease. A repeat screening at least 8 weeks after the last exposure may also be necessary. Step 1: Initial Screening A. Obtain a medical history including prior TB screening and TB treatment information Determine if the patient has any immunocompromising conditions or other conditions that put the patient at an increased risk of progression from latent TB infection (LTBI) to active TB disease. For purposes of TB screening, the following are immunocompromising conditions of concern: HIV infection with CD4 count <200 Stem cell or solid organ transplant recipients receiving immunosuppressive medications Daily treatment with moderate/high dose corticosteroid (equivalent to prednisone 15 mg) Treatment with a TNF-alpha antagonist Poorly controlled diabetes (most recent hemoglobin A1c >9%) Receiving dialysis or has uremia Leukemia or lymphoma Cancer of head, neck, or lungs Receiving chemotherapy for any neoplasm Nephrotic syndrome Protein losing enteropathy Protein energy malnutrition Age <5 years Other (non-immunocompromising) conditions that increase risk of progression to active TB include: Controlled diabetes Silicosis Gastrectomy or jejunal bypass Tobacco use 9/6/2017 1

2 B. Screen for the following TB symptoms: Screen for the following TB symptoms: cough 3 weeks, hemoptysis, shortness of breath, night sweats, fevers or chills, or unintentional weight loss. If the symptom screen is done <8 weeks from the date of last exposure to TB, the symptom screen must be repeated at least 8 weeks after the date of last exposure (ideally 8 10 weeks after last exposure). Patients reporting cough of <3 weeks duration at the time of screening should have follow-up to determine if the cough has resolved. If they have a persistent cough for 3 weeks, further evaluation is indicated. C. Obtain a TB screening test (i.e., interferon-gamma release assay [IGRA] or tuberculin skin test [TST]) if the person has no documented prior positive IGRA or TST. An IGRA (QuantiFERON -TB Gold [QFT-G], or T-SPOT TB test [T-Spot]) is the preferred test for contacts who originate from areas where they likely received BCG vaccine or are unlikely to return for reading of a TST. A TST result of 5 mm of induration is considered positive for persons exposed to infectious TB cases. A TST should be performed for children <5 years old. If the TB screening test is negative and was performed <8 weeks from the date of last exposure to TB, a screening test must be repeated at least 8 weeks after the date of last exposure (ideally 8 10 weeks after last exposure). Contacts with prior positive TST or IGRA results DO NOT need a new TST or IGRA performed. Instead, they should be considered to have a positive TB screening test. In the event a person with a past positive TST or IGRA has a new TST or IGRA performed and it is negative, the significance of the new screening test is uncertain, please contact MDH ( ) to discuss these discrepant results with a physician or nurse in the TB control unit. D. Determine if a chest x-ray is needed, as follows: For contacts who were clients of the Hmong senior center where documented MDR TB transmission occurred, and for any other types of exposures that MDH or local public health determine to represent very high risk settings for MDR TB transmission, obtain a chest x-ray, regardless of TB screening test or symptom screening results. If uncertain if a patient falls into this category, contact MDH ( ) or your local public health department. All contacts who have a previously documented positive IGRA or TST, or a history of LTBI or active TB, regardless of treatment history, require a chest x-ray. For all other contacts, obtain a chest x-ray if the TB screening test is positive, the person is immunocompromised or < 5 years old, or if the person has any of the TB symptoms listed in step 1B. Step 2: Rule out Active Disease A. Determine if a provider visit is needed The following contacts should be directly evaluated by a provider as soon as possible (i.e., do not wait until the results of repeat assessments performed 8 10 weeks after last TB exposure if any the following criteria are identified at the initial screening): 9/6/2017 2

3 Any person with symptoms compatible with TB Any person with a prior or new positive IGRA or TST Any person with an abnormal chest x-ray compatible with TB Any person with a history of LTBI or active TB, regardless of treatment history Any person with an immunocompromising condition or a child < 5 years old B. Physical exam and testing to evaluate for active TB For patients that require a provider visit, perform a thorough review of systems and physical exam to assess for abnormalities including extrapulmonary sites of infection. The following patients must be tested for active pulmonary TB: Symptomatic patients (defined as cough lasting 3 weeks, or hemoptysis, or 2 of the other symptoms listed in step 1B) regardless of TB screening test result. Patients with chest x-ray abnormalities that could be consistent with active pulmonary TB disease, regardless of medical history or TB screening test result. C. Test for active pulmonary TB Obtain 3 sputum samples for AFB smear and AFB culture, and, for 2 of the 3 samples, Mycobacterium tuberculosis PCR. Notify MDH ( ) whenever ordering sputum samples for TB testing. Patients should stay in home isolation while waiting for smear and PCR results. Continued avoidance of public settings will be made on a case-by-case basis while awaiting culture results. D. Negative sputum testing does not necessarily rule out active TB. If a patient has symptoms or radiological findings concerning for TB, consult with a TB expert before fully ruling out active TB. Additional testing may be required to rule out active disease, including, but not limited to, chest CT or other imaging, bronchoscopy, or further assessment for extrapulmonary TB. If active disease is diagnosed, refer patient to a TB expert for treatment. If active disease has been ruled out, proceed to step 3. Step 3: Determine Diagnosis After active disease has been ruled out, place patient into one of the following five categories and follow the management guidance listed. Category 1. History of inadequately treated LTBI or active TB. See steps 4A, 4B, and 4C. Category 2. History of adequately treated LTBI or active TB. See step 4D. 9/6/2017 3

4 Category 3. Newly detected LTBI (i.e., new positive TB screening test) See steps 4A, 4B, and 4C. Category 4. No evidence of LTBI (i.e. negative TB screening test) If not immunocompromised: no further follow-up needed if most recent TB screening test and symptom screen were obtained >8 weeks after last known TB exposure (if not, repeat TB screening test and symptom screen 8-10 weeks after last exposure). If immunocompromised or contact is a child <5 years old: call MDH to consult with an MDR TB expert because these patients may need window prophylaxis and likely should be treated as outlined in steps 4A, 4B, and 4C. Category 5. TB screening test indeterminate Repeat TB screening test. If repeat TB screening test remains indeterminate, call MDH to consult with an MDR TB expert. Step 4: LTBI Treatment or 2-year Monitoring Before starting a patient on treatment for LTBI, ensure active TB disease has been ruled out as described above (step 2) and screen for factors that increase the risk of adverse events (step 5). A. Administer 9 months of treatment for presumed MDR LTBI For persons 15 years old: Moxifloxacin 400 mg by mouth daily For persons <15 years old: Levofloxacin mg/kg by mouth daily (not to exceed 750 mg daily) B. If patient unable to tolerate Moxifloxacin due to side effects (e.g., headache, dizziness, nausea, vomiting, diarrhea, abdominal pain, tendonitis, peripheral neuropathy, arthralgias, etc.) Switch to Levofloxacin For persons 18 years old: Levofloxacin 500mg by mouth daily if 45.5kg; 750 mg by mouth daily if >45.5kg For persons <18 years old: Levofloxacin mg/kg by mouth daily (not to exceed 750 mg daily) Renal failure/dialysis: Levofloxacin mg/dose 3 times weekly for creatinine clearance <30 ml/min If unable to tolerate both Moxifloxacin and Levofloxacin: discontinue treatment and monitor for the next 2 years as outlined in step 4C. 9/6/2017 4

5 C. If patient refuses treatment or is unable to take fluoroquinolones due to other medical reasons Monitor patient for 2 years. (The period of follow-up is based on the date of the first chest x-ray after the last date of TB exposure, aka baseline chest x-ray. Patients may require to be monitored for more than 2 years if they were re-exposed to MDR TB after starting monitoring). At 3 months after baseline chest x-ray: Provider visit with symptom screen and physical exam. At 6, 12, 18, and 24 months after baseline chest x-ray: Chest x-ray and provider visit to include symptom screen and physical exam. Educate patient about the need to notify their medical provider if the patient becomes symptomatic at any time during the 2-year follow-up period. Initiate evaluation for active TB immediately if symptoms or chest x-ray abnormalities develop during the follow-up period. D. For those who have previously completed treatment for either drug resistant or pan-susceptible LTBI or active TB. The need for treatment of MDR LTBI should be made on an individual basis. In general: For immunocompromised patients or patients with comorbidities associated with increased risk of TB reactivation, and/or patients with history of completed treatment for either active TB or LTBI 10 years ago Encourage treatment with MDR LTBI regimen as outlined in steps 4A and 4B. If patient refuses treatment or is unable to take fluoroquinolones due to other medical reasons, monitor them for the next 2 years as outlined in step 4C. If not immunocompromised and no comorbidities associated with increased risk of TB reactivation, and active TB treatment/ltbi treatment was completed <10 years ago Treatment for MDR LTBI is likely unnecessary. Monitor for the next 2 years as outlined in step 4C. Step 5: Screening for Adverse Events While on treatment patients should be evaluated every month using the MDH MDR LTBI Treatment Monitoring Flow Sheet to ensure adequate screening for side effects at each monthly medical visit. Fluoroquinolones can lower blood glucose, cause tendinitis, peripheral neuropathy, and prolong the QTc interval which, rarely, can lead to life-threating arrhythmias. Screen patients for medical conditions and for potential medication interactions that could increase the risk of adverse events associated with Moxifloxacin and Levofloxacin before starting MDR LTBI treatment. Persons with congenital prolonged QT syndromes should not be offered a fluoroquinolone; they should be monitored for 2 years. 9/6/2017 5

6 For persons with electrolyte abnormalities, bradycardia, ischemic heart disease, intracranial disease, HIV infection, hepatic impairment, connective tissue diseases with anti-ro/ssa antibodies, and persons who are taking a medication known to prolong the QTc interval, obtain a baseline ECG before starting MDR LTBI treatment and a repeat ECG 1 2 weeks after starting treatment. For a list of QTc prolonging medications go to the Credible Meds website ( Take a complete history of all patients medications at each monthly clinic visit. If the patient reports a new QTc prolonging medication, continue the fluoroquinolone and obtain an ECG at time of first report of the new medication and then again in 1-2 weeks. If the QTc is longer than normal ( 0.44 seconds among children 1 15 years old, 0.43 seconds among males >15 years, or 0.45 seconds among females >15 years, or if the QTc increases by >25% during the course of treatment), consult with a cardiologist before starting or continuing MDR LTBI treatment. While taking MDR LTBI treatment, patients should be instructed to promptly report any new palpitations or fainting which may be signs of QTc prolongation. Patients should be educated on the small risk of tendinitis related to fluoroquinolone use and that the concomitant use of corticosteroids with fluoroquinolones may increase the risk for tendinopathy. The risk of tendinitis may also be increased among patients with kidney failure and rheumatoid arthritis Patients taking medications to lower blood glucose, especially oral hypoglycemic agents, should be notified to check their blood sugar closely while taking a fluoroquinolone and to contact their primary care provider immediately if blood glucose levels are measuring lower than normal so oral hypoglycemic dosage(s) can be adjusted. Moxifloxacin and levofloxacin may worsen muscle weakness among patients with myasthenia gravis. Persons with renal insufficiency require dosing adjustment for levofloxacin, but not for Moxifloxacin as outlined in step 4B. Although the risk of liver damage with fluoroquinolones is low, all patients should be notified to stop taking the fluoroquinolone if they develop jaundice. References 1. Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, Jonas DE. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016; 316(9): doi: /jama Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Clinical Infectious Diseases, Volume 64, Issue 2, 15 January 2017, Pages , 9/6/2017 6

7 TB Screening Flow Diagrams for Contacts of Infectious MDR TB Disease Part A: High transmission risk groups (e.g., Hmong Senior Center Attendees) 9/6/2017 7

8 Part B: All other contacts 9/6/2017 8

9 Footnotes MDR TB EXPOSURE SCREENING AND TREATMENT RECOMMENDATIONS a IGRAs are the preferred test for persons who originate from areas where they likely have received BCG vaccine. TST should be done for children <5 years old. TST result of 5 mm of induration is considered positive for persons exposed to infectious TB cases. Persons with previous positive TST or IGRA do not need a repeat TST or IGRA and instead should be considered TST/IGRA positive. b Cough lasting 3 weeks, hemoptysis, shortness of breath, night sweats, fevers or chills, or unintentional weight loss. If the symptom screen is done <8 weeks from the date of last exposure to TB, the symptom screen must be repeated at least 8 weeks after the date of last exposure. c Medical history includes prior TB screening and treatment, immunocompromising conditions (see footnote d) and other conditions that increase risk of progression from latent TB infection to active TB disease (i.e., controlled diabetes mellitus, silicosis, gastrectomy, jejunal bypass, and tobacco use). d Immunocompromising conditions include the following: HIV infection with CD4 count <200, stem cell or solid organ transplant recipients receiving immunosuppressive medications, daily corticosteroid use equivalent to prednisone 15 mg, use of TNF-alpha antagonist, poorly controlled diabetes mellitus with Hgb A1c >9%, dialysis, uremia, leukemia, lymphoma, cancer of head, neck, or lungs, currently receiving chemotherapy, nephrotic syndrome, protein losing enteropathy, protein energy malnutrition, age <5 years. For immunocompromised persons, consult with TB experts. e Additional testing may include induced sputum collection, other chest imaging (e.g., CT scan), bronchoscopy, or imaging or specimen collection to assess for extrapulmonary TB. f Immunocompetent contacts with a history of completed treatment for susceptible LTBI (INH x 6-9 months, rifampin x 4 months, or INH + rifapentine x 3 months) within the past 10 years likely do not require MDR LTBI treatment if they don t have other comorbidities associated with increased risk of TB activation, but still require monitoring for active TB disease for 2 years following last known MDR TB exposure. g Baseline chest x-ray is defined as the first chest x-ray after the last date of TB exposure Minnesota Department of Health Tuberculosis Prevention and Control Program PO Box St. Paul, MN To obtain this information in a different format, call Printed on recycled paper. 9/6/2017 9

Northwestern Polytechnic University

Northwestern Polytechnic University Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Diagnosis and Medical Management of Latent TB Infection

Diagnosis and Medical Management of Latent TB Infection Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,

More information

Contact Investigation and Prevention in the USA

Contact Investigation and Prevention in the USA Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis

More information

Tuberculosis Tools: A Clinical Update

Tuberculosis Tools: A Clinical Update Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

Tuberculosis in Pregnancy

Tuberculosis in Pregnancy Tuberculosis in Pregnancy 1. Screening for Latent Tuberculosis Infection (LTBI) WHO to screen? Those at high risk for contracting TB and converting from latent to active TB Known HIV infection Close contact

More information

Chapter 5 Treatment for Latent Tuberculosis Infection

Chapter 5 Treatment for Latent Tuberculosis Infection Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI

More information

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection

More information

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN

More information

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)

More information

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed

More information

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

TUBERCULOSIS. Presented By: Public Health Madison & Dane County TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with

More information

Tuberculosis: A Provider s Guide to

Tuberculosis: A Provider s Guide to Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency

More information

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.

More information

INDEX CASE INFORMATION

INDEX CASE INFORMATION Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.

More information

UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form

UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form UC DavisTB Screening Requirement: How to submit your TB Health Assessment Form Step 1 If after completing the TB Risk Screening you are found to be at high risk, you must complete the Tuberculosis (TB)

More information

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014 What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks

More information

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017 Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

LATENT TUBERCULOSIS. Robert F. Tyree, MD

LATENT TUBERCULOSIS. Robert F. Tyree, MD LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION

More information

Latent Tuberculosis Best Practices

Latent Tuberculosis Best Practices Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States

More information

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and

More information

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population

More information

LTBI Videos-Treatment

LTBI Videos-Treatment LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of

More information

Latent tuberculosis infection

Latent tuberculosis infection EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent

More information

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will

More information

TB in Corrections Phoenix, Arizona

TB in Corrections Phoenix, Arizona TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from

More information

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening

More information

Peggy Leslie-Smith, RN

Peggy Leslie-Smith, RN Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH

More information

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017 The Diagnosis of Active TB Deborah McMahan, MD TB Intensive September 28, 2017 Agenda Epidemiology Big picture Conditions that Should Make You Suspicious Which test? Eeenie meenie miny mo Radiographic

More information

Management of Pediatric Tuberculosis in New Jersey

Management of Pediatric Tuberculosis in New Jersey Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis

More information

Contact Investigation

Contact Investigation Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period

More information

Tuberculosis Update. Topics to be Addressed

Tuberculosis Update. Topics to be Addressed Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division

More information

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016 Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,

More information

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with

More information

Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18

Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18 Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department

More information

TUBERCULOSIS. Pathogenesis and Transmission

TUBERCULOSIS. Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are

More information

A look at medical factors that increase the risk for TB disease

A look at medical factors that increase the risk for TB disease A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune

More information

My heart is racing. Managing Complex Cases. Case 1. Case 1

My heart is racing. Managing Complex Cases. Case 1. Case 1 Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from

More information

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,

More information

Please distribute a copy of this information to each provider in your organization.

Please distribute a copy of this information to each provider in your organization. HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to

More information

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000

More information

TB Clinical Guidelines: Revision Highlights March 2014

TB Clinical Guidelines: Revision Highlights March 2014 TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,

More information

TUBERCULOSIS CONTACT INVESTIGATION

TUBERCULOSIS CONTACT INVESTIGATION TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the criteria used

More information

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case

More information

LTBI: Who to Test & When to Treat

LTBI: Who to Test & When to Treat LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report

More information

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology

More information

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility

More information

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal

Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB

More information

Tuberculosis Populations at Risk

Tuberculosis Populations at Risk Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading

More information

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening

More information

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society

More information

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director Tuberculosis What you need to know James Zoretic M.D., M.P.H. Regions 2 and 3 Director What is Tuberculosis? Tuberculosis, (TB) is a communicable disease caused by the Mycobacterium tuberculosis bacillus

More information

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How

More information

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)

Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254) Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to

More information

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014 Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB

More information

Community pharmacy-based tuberculosis skin testing

Community pharmacy-based tuberculosis skin testing Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences

More information

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International

More information

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010 TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS

More information

TB in the Patient with HIV

TB in the Patient with HIV TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to

More information

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either

More information

LTBI in Special Populations John Nava, MD October 5, 2010

LTBI in Special Populations John Nava, MD October 5, 2010 Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 LTBI in Special Populations John Nava, MD October 5, 2010 2 Treatment of Latent TB Infection in Special Populations John

More information

What Drug Treatment Centers Can do to Prevent Tuberculosis

What Drug Treatment Centers Can do to Prevent Tuberculosis What Drug Treatment Centers Can do to Prevent Tuberculosis Tuberculosis (TB) is alive and well Learn what you can do to prevent TB among your clients and protect yourself! Transmission TB is spread through

More information

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No

More information

Self-Study Modules on Tuberculosis

Self-Study Modules on Tuberculosis Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control

More information

Latent TB, TB and the Role of the Health Department

Latent TB, TB and the Role of the Health Department Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or

More information

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Revised Technical Instructions for Civil Surgeons. October 9, 2018 Revised Technical Instructions for Civil Surgeons October 9, 2018 Speakers Joanna Regan Centers for Disease Control and Prevention Shereen Katrak California Department of Public Health Pennan Barry California

More information

New Standards for an Old Disease:

New Standards for an Old Disease: New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At

More information

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active

More information

FLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES

FLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES FLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES Superintendent Signature Designated Health Authority Signature Effective Date: November 1, 2016 Subject: TUBERCULOSIS

More information

CHAPTER 3: DEFINITION OF TERMS

CHAPTER 3: DEFINITION OF TERMS CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria

More information

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB the basics. (Dr) Margaret (DHA) and John (INZ) TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2

More information

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI: Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global

More information

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide Asking the Right Questions A Visual Guide to Tuberculosis Case Management for Nurses Reference Guide The Francis J. Curry National Tuberculosis Center is a joint project of the San Francisco Department

More information

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.

More information

CDC IMMIGRATION REQUIREMENTS:

CDC IMMIGRATION REQUIREMENTS: CDC IMMIGRATION REQUIREMENTS: Technical Instructions for Tuberculosis Screening and Treatment Using Cultures and Directly Observed Therapy October 1, 2009 Table of Contents Preface...i Tuberculosis Screening...1

More information

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate

More information

Primer on Tuberculosis (TB) in the United States

Primer on Tuberculosis (TB) in the United States Primer on Tuberculosis (TB) in the United States The purpose of this primer is to provide instructors who have no prior background in TB research or clinical care with basic knowledge that they may find

More information

Questions and Answers About

Questions and Answers About Questions and Answers About TB 2005 DEPARTMENT OF HEALTH AND HUMAN SERVICES TB Elimination Questions and Answers About TB 2005 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

More information

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:

More information

LTBI Treatment and Anti TNF alpha

LTBI Treatment and Anti TNF alpha LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages

More information

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis? Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able

More information

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or

More information

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015 Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts

Communicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Assessment and Follow-Up of TB July, 2018 Page 1 TABLE OF CONTENTS 8.0 ASSESSMENT AND

More information

Ongoing Research on LTBI and Research priorities in India

Ongoing Research on LTBI and Research priorities in India Ongoing Research on LTBI and Research priorities in India Dr. C.Padmapriyadarsini, MD, MS ICMR-National Institute for Research in Tuberculosis Chennai, India Technical Consultation Meeting on Programmatic

More information

TB Intensive San Antonio, Texas May 7-10, 2013

TB Intensive San Antonio, Texas May 7-10, 2013 TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant

More information

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009 TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages

More information

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculosis (TB) Fundamentals for School Nurses Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of

More information

New Tuberculosis Guidelines. Jason Stout, MD, MHS

New Tuberculosis Guidelines. Jason Stout, MD, MHS New Tuberculosis Guidelines Jason Stout, MD, MHS Two New Sets of Guidelines Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases 2016; 63(7): e147-e195 Diagnosis of Tuberculosis in Adults

More information

Ian Kitai TB Specialist. Division of Infectious Diseases Sickkids

Ian Kitai TB Specialist. Division of Infectious Diseases Sickkids Ian Kitai TB Specialist Division of Infectious Diseases Sickkids Review Clinical presentation of TB disease childhood How to assess risk for TB infection How to assess risk for disease if infected TST

More information

Self-Study Modules on Tuberculosis

Self-Study Modules on Tuberculosis Self-Study Modules on Tuberculosis Transmission and Pathogenesis of Tube rc ulos is U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for HIV/AIDS,

More information